KeyBanc analyst Matthew Gillmor upgraded BrightSpring Health (BTSG) to Overweight from Sector Weight with a $45 price target following meetings with management. The firm sees the company’s EBITDA estimates for 2026 and 2027 moving higher, supported by limited distribution drug portfolio wins, generic conversions, operational initiatives, and the pending Amedisys deal. The acquisition of 127 home health locations could be a source of underappreciated EBITDA upside for 2026 and beyond, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- Stephens starts BrightSpring at Overweight, cites heightened growth profile
- BrightSpring Health initiated with an Overweight at Stephens
- BrightSpring Health price target raised to $41 from $38 at BofA
- BrightSpring Health Services: Strategic Growth and Expansion Drive Promising Outlook
- BrightSpring Health initiated with an Outperform at William Blair